 |
 |
 |
 |
 |
 |
 |
 |
-
BROWSE TOPICS IN CLINICAL MANAGEMENT:
Antiretroviral Therapy- Complications of HIV/HAART
- Research & Development
- Clinical Trials
- Quality of Life & Patient Care
Antiretroviral Therapy
Etravirine (TMC125, Intelence)
 |
| Click here for a summary of the essential details on etravirine (TMC125, Intelence) from Cal Cohen, M.D. |
Overview
- A Clinical Overview of Etravirine (TMC125, Intelence) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health - Drug Watch: Next-Generation NNRTIs: Etravirine and Rilpivirine (Winter 2008)
To read PDF, click here
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation - News Analysis: U.S. Approval of Etravirine (Intelence) (January 25, 2008)
An interview with Cal Cohen, M.D., M.S.
From The Body PRO - Project Inform Welcomes Approval and Pricing of Intelence, Calls for Further Research (January 23, 2008)
From Project Inform - Etravirine (TMC125, Intelence) Approved by U.S. FDA (January 19, 2008)
From U.S. Food and Drug Administration - Prescribing Information for Etravirine (TMC125, Intelence) (PDF) (January 2008)
From Tibotec Therapeutics
News & Research
- AAHIVM Encouraged by TMC125 Approval (January 22, 2008)
New HIV medication could offer more options for treatment-experienced patients.
From American Academy of HIV Medicine - Fair Pricing Coalition Lauds Pricing of New Tibotec Drug (January 21, 2008)
From Fair Pricing Coalition - Information on Etravirine Expanded Access Program in United States (January 2008)
EAP closed; application still accessible for entry of follow-up data on enrolled patients.
From Tibotec Pharmaceuticals Ltd. - Another Look at TITAN and DUET: How Will They Change Clinical Practice? (July 25, 2007)
In The 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO - The Bottom Line on Darunavir, Etravirine, Raltegravir, Maraviroc (July 25, 2007)
In The 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO - FDA Receives New Drug Application for TMC125 (Etravirine) (July 20, 2007)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Efficacy and Safety of TMC125 (Etravirine) in Treatment-Experienced HIV-1-Infected Patients in DUET-1: 24-Week Results From a Randomised, Double-Blind, Placebo-Controlled Trial (July 7, 2007)
In The Lancet - Efficacy and Safety of TMC125 (Etravirine) in Treatment-Experienced HIV-1-Infected Patients in DUET-2: 24-Week Results From a Randomised, Double-Blind, Placebo-Controlled Trial (July 7, 2007)
In The Lancet - No Patient Left Behind -- Better Treatments for Resistant HIV Infection (July 7, 2007)
A commentary accompanying the publication of the DUET study results comparing etravirine + darunavir/ritonavir to darunavir/ritonavir without etravirine. (Article accessible only to paid subscribers.).
In The Lancet - Adding Etravirine to Darunavir/Ritonavir Improves Virologic Suppression, DUET Studies Show (July 6, 2007)
From aidsmap.com - Tibotec Pharmaceuticals Ltd. Announces Expanded Access Program for Its Investigational Agent TMC125 (September 25, 2006)
Program will provide early access for eligible HIV-1-infected patients who have limited treatment options.
From Tibotec Pharmaceuticals Ltd. - Behind the December 2004 "AIDS Breakthrough" Headlines (December 31, 2004)
Mid-December press reports were exaggerated, but still important; they focus on DAPYs, a promising new family of HIV meds.
In AIDS Treatment News, from AIDS Treatment News - Research Updates on Tipranavir, TMC-114 and TMC-125 (December 2004)
A review of the tipranavir RESIST studies, a note on potential tipranavir pricing, and a critical look at two developing rescue drugs.
In TAGline, from Treatment Action Group - An Interview With Dr. Cal Cohen on Highlights From the 10th Conference on Retroviruses and Opportunistic Infections (April 4, 2003)
In AIDS Treatment News, from AIDS Treatment News - TMC125 Monotherapy for 1 Week Results in a Similar Initial Rate of Decline of HIV-1 RNA as Therapy With a Five-Drug Regimen (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - TMC125 Is a Highly Potent Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) in Antiretroviral Therapy (ART)-Naive, HIV-1 Infected Subjects (December 17, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO - One Week of Monotherapy with TMC-125, a Novel Highly Potent NNRTI, Produces a Mean 2-Log Reduction in Viral Load in Antiretroviral-Naive, HIV-1-Infected Volunteers (October 28, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
  |
  |